Synthesis,Crystal Structure and Anticoagulant Activity of 5-Chloro-N-[[（5S）-2-oxo-3-[4-（2- oxopyridin-1 （2H）-yl）phenyl] oxazolidin-5- yl] methyl] thiophene-2-carboxamide①

The title compound(zifaxaban 2, C20H16ClN3O4 S, Mr = 429.87) was synthesized and its crystal structure was determined by single-crystal X-ray diffraction. Zifaxaban crystallizes in monoclinic, space group P21 with a = 5.7900(12), b = 13.086(3), c = 12.889(3) A, β = 100.86(3)°, V = 959.1(3) A3, Z = 2, Dc = 1.489 g/cm3, F(000) = 444, μ = 0.342 mm-1, the final R = 0.0320 and wR = 0.0640 for 2717 observed reflections(I 2σ(I)). The absolute configuration of the stereogenic center in the title compound was confirmed to be S by single-crystal X-ray diffraction. Four existing intermolecular hydrogen bonds help to stabilize the lattice and the molecule in the lattice to adopt an L-shape conformation. Zifaxaban was slightly more active than rivaroxaban 1 in in vitro assay against human FXa and therefore is promising as a drug candidate.     

新型N-(2-氧代-2-苯基乙基)-4,5,6,7-四氢噻吩并[3,2-c]吡啶酯类衍生物的合成及其抗血小板聚集活性

以5-三苯甲基-5,6,7,7a-四氢噻吩[3,2-c]吡啶-2(4H) 酮为起始原料，依次经酯化、脱保护和亲核取代反应合成了17个新型的N-(2-氧代-2-苯基乙基)-4,5,6,7-四氢噻吩并[3,2-c]吡啶酯(1a~1q)；并以2-溴-1-环丙基-2-(2-氟苯基)乙酮合成了新的普拉格雷衍生物(6)，其结构均经¹H NMR和MS(ESI)表征。并通过“ADP对大鼠血小板聚集的影响”的药效学模型初步评价了其抗血小板聚集活性。结果表明：1f， 1p， 1q和6对血小板聚集有一定的抑制作用，其中6在低剂量(3 mg·kg^-1)下的活性优于阳性对照药氯吡格雷。     

人血浆中吲哒帕胺的测定

在碱性条件下用二氯甲烷提取,以甲磺酸多沙唑嗪为内标,采用XDBC18反相柱(5μ),质谱检测器采用AP-ESI,正离子模式,采集方式为SIM,流动相为乙腈-水-醋酸-醋酸铵(50:50:0.1:0.2,V/V),用液相色谱-质谱联用法(LC-MS)测定人血浆中吲哒帕胺浓度.吲哒帕胺在1-150ng/mL范围内线性关系良好,提取回收率大于80%,精密度(RSD)均小于10%,检出限为1.0ng/mL.该法方便、准确、灵敏,适用于吲哒帕胺缓释制剂的药代动力学研究,也可以用于临床测定吲哒帕胺血浆药物浓度.     

肽脱甲酰化酶抑制剂的合成及其抑菌活性

通过对肽脱甲酰化酶抑制剂构效关系的研究,以放线酰胺素为先导化合物,设计并合成了一系列异噁唑类化合物。其结构经1H NMR,IR,MS和元素分析表征。生物活性实验表明,该类化合物对标准肺炎克雷白球菌有显著的抑菌活性。